Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug.

Of all attempts towards developing a follow on biologics or a biosimilar drug the main detection point stands at the bioequivalence assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable biologics or biosimilars.

 

  • Strategies for the bioequivalence assessment of topical dosage forms
  • Bioequivalence approaches for transdermal dosage forms
  • Bioequivalence assessment of respiratory dosage forms
  • Evaluation of highly variable drugs and drug products

Related Conference of Bioequivalence Assessment

February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
February 27-28, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland

Bioequivalence Assessment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in